Lyme disease vaccine

Lyme disease is the most common tick-borne infection in the United States, with more than 12,000 cases reported annually (1). The disease is characterized by a rash (erythema migrans) and various systemic (nervous, cardiac and musculoskeletal) manifestations; clinical manifestations of Lyme disease were reviewed recently (2). Most cases of Lyme disease in the United Sates are reported from the northeastern, mid-Atlantic and upper north central states, and from a part of northwest California. Lyme disease is caused by the spirochete Borrelia burgdorferi, and it is transmitted by the deer tick Ixodes scapularis in the eastern and mid-western states, and Ixodes pacificus in the Pacific coast states. Transmission occurs primarily through bites acquired during the nymphal stage of the life cycle of the ticks, which feed predominantly in the late spring and early summer. Two vaccines that protect against Lyme disease have been developed; one has been licensed for use in Canada recently. Answers to common questions about the Lyme disease vaccine follow. Lyme disease is not common in Canada. Although it is not a reportable disease in most provinces, less than 30 cases are reported each year (3). In Canada, Lyme disease can be acquired in areas where the tick vector is well established. More than half of the cases of Lyme disease from these areas, and virtually all of the cases from nonendemic areas, can be linked epidemiologically to travel to a highly endemic area of the United States. Not all ticks can transmit Lyme disease. The common dog tick (Dermacentor variabilis) is not a capable vector for the Lyme disease spirochete. Only the deer tick (I scapularis and I pacificus) is involved in the life cycle of B burgdorferi, and it transmits the disease. Although I scapularis has been found in all provinces from Saskatchewan to the east, and I scapularis was demonstrated to be carrying B burgdorferi in some of these ticks, most ticks have been adult females most likely brought to Canada on migratory birds and have not undergone their full life cycle in Canada (4–7). In fact, I scapularis is established (having larva, nymph and adult stages present) only in the Long Point peninsula and Point Pelee National Park, both on Lake Erie in Ontario, whereas I pacificus undergoes its full reproductive cycle in Canada only in the Fraser River delta, the Gulf Islands and Vancouver Island of British Columbia (8). At present, one Lyme disease vaccine (LYMErix, SmithKline Beecham, Oakville, Ontario) is licensed for use in Canada. A second Lyme disease vaccine (ImuLyme, Aventis Pasteur, Toronto, Ontario) is not yet licensed in Canada. Both vaccines use recombinant B burgdorferi lipidated outer surface protein A (rOspA) to induce protective antibodies. The following information refers to LYMErix, which has been approved for use in Canada, although reported results with ImuLyme are similar (9). LYMErix was compared with placebo in an endemic area in 10,936 healthy individuals who were given three doses of the vaccine at 0 months, one month and 12 months (10). In the year after two doses of vaccine were given, symptomatic, laboratory-confirmed Lyme disease occurred in 22 LYMErix recipients and 43 placebo recipients (vaccine efficacy 49%, 95% CI 15% to 69%). After the third dose was administered at 12 months, Lyme disease was diagnosed in 16 vaccine recipients and 66 placebo recipients giving a vaccine efficacy of 76% (95% CI 58% to 86%). In the prelicensure efficacy study (10), LYMErix recipients had more frequent reports at the injection sites than placebo recipients of soreness (24.1% compared with 7.6%, respectively), erythema (1.8% compared with 0.5%) and swelling (0.9% compared with 0.2%). Systemic adverse events were less commonly reported, and they were more common after the use of LYMErix than placebo (ie, fever 2.0% compared with 0.8%; myalgia 3.2% compared with 1.8%; influenzae-like illness 2.0% compared with 1.1%). Adverse events usually were reported in the first 48 h after immunization, and lasted a median of three days. Vaccination should only be considered as an adjunctive measure to avoid Lyme disease. Personal control measures such as avoiding tick-infested areas, covering exposed skin, wearing light coloured clothing to allow easier observation and removal of ticks, examination for ticks each evening, and tick repellents are all important measures in preventing Lyme disease. Lyme disease vaccine should be given to individuals who are 15 years of age or older, and who, because of their recreational activity or occupation, cannot avoid exposure to ticks in an endemic area. A risk assessment should be made to determine the advisability of being immunized (1). Persons at high risk are those who live in, or visit, areas of high or moderate risk, and who engage in activities (eg, recreational, occupational and property maintenance) that result in frequent or prolonged exposure to a tick-infested habitat. Vaccine should be considered for these individuals. Persons at moderate risk are those who live in, or visit, areas of high or moderate risk, and who are exposed to a tick-infested habitat but whose exposure is neither frequent nor prolonged. Lyme disease vaccine may be considered for these individuals. Persons at low or no risk are those who live in areas of low or no risk, or those who live in, or visit, areas of moderate or high risk but have minimal or no exposure to Lyme disease vector ticks. Lyme disease vaccine should not be given to persons who are at low or no risk of acquiring the disease; most Canadians fit into this category. In addition, Lyme disease vaccine should not be given during pregnancy or to children under 15 years of age (until safety data are available). There are no data on the safety or efficacy of Lyme disease vaccine in people with immunodeficiencies. Lyme disease vaccine should not be given to individuals with a history of treatment-resistant Lyme disease because of the association of this condition with abnormal immune reactivity to OspA. Three doses of Lyme disease vaccine are required to provide optimal protection. The first two doses (at 0 months and one month) should be timed so that maximal protection (one month after the second dose) immediately precedes the beginning of the tick's nymphal stage feeding season (April). This ensures that the third dose at 12 months immediately precedes the subsequent tick season. It is not known yet whether additional booster doses will be required for subsequent seasons. The risk of acquiring Lyme disease is so low in Canada that universal immunization with Lyme disease vaccine is not advisable. In fact, it would not be cost beneficial to immunize everyone even in highly endemic communities in the United States (11). Therefore, a risk assessment that analyzes the likelihood of exposure to Lyme disease provides the most cost effective method of using this vaccine. The risk of acquiring Lyme disease, even in endemic areas of the United States, is very localized (ie, relating to communities rather than counties or states). The most up-to-date information about areas of risk can be obtained from local public health authorities. Detailed American recommendations for the use of Lyme disease vaccine have been published in the Morbidity and Mortality Weekly Report (1); Canadian guidelines from the National Advisory Committee on Immunization will be published soon in the Canada Communicable Disease Report. The product monograph should be consulted for specific prescribing information.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.